SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002; 14: 2430.
  • 2
    Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 15971603.
  • 3
    Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52: 363371.
  • 4
    Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev 1998; 12: 145153.
  • 5
    Lopez A, de la Rubia J, Martin G, et al. Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 2001; 25: 685692.
  • 6
    Piccaluga PP, Martinelli G, Rondoni M, et al. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly. Haematologica 2003; 88: ECR37.
  • 7
    Resegotti L. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 1992; 6 ( Suppl 2): 7275.
  • 8
    Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 4784.
  • 9
    Poulain S, Lepelley P, Preudhomme C, et al. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 2000; 110: 591598.
  • 10
    Larson RA. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia 1996; 10 ( Suppl 1): S23S25.
  • 11
    Tourneur L, Delluc S, Levy V, et al. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 2004; 64: 81018108.
  • 12
    Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 13121320.
  • 13
    Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study. J Clin Oncol 2005; 23: 482493.
  • 14
    Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001; 40: 231252.
  • 15
    Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389395.
  • 16
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia.Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896903.
  • 17
    Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548553.
  • 18
    ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification, 5th ed., 1999. Los Angeles: Practice Management Information Corporation,1998.
  • 19
    Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19: 603610.
  • 20
    Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998; 100: 629636.
  • 21
    Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Society of Clinical Oncology survey.Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol 1999; 10: 13551359.
  • 22
    Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004; 12: 219226.
  • 23
    Mitchell CL, Anderson ERJr, Braun L. Billing for inpatient hospital care. Am J Health Syst Pharm 2003; 60: S8S11.
  • 24
    Westerman IL, Bennett CL. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation. Stem Cells 1996; 14: 312319.
  • 25
    Friedman B, De La Mare J, Andrews R, McKenzie DH. Practical options for estimating cost of hospital inpatient stays. J Health Care Finance 2002; 29: 113.
  • 26
    Centers for Medicare & Medicaid Services. Acute inpatient prospective payment system. Available at http://www.cms.hhs.gov/providers/hipps/ippsotlr.asp 2005.
  • 27
    Katz LM, Stern LS, Fastenau JM, Piech CT, Doyle JJ. Trends in outcomes and charges of acute myeloid leukemia in the elderly: A cross-sectional analysis of the nationwide inpatient sample from 1993 to 2001. In the Annual Meeting of the American Society of Hematology, San Diego, CA, December 2004.